# Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

> **NCT03029234** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 126 (actual)

## Conditions studied

- Relapsed and Refractory Multiple Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT03029234
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-31
- **Primary completion:** 2018-11-05
- **Final completion:** 2021-06-04
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029234, "Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03029234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*